By Hugo Francisco de Souza New research reveals how GLP-1 medications are reshaping the treatment landscape for conditions ...

Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

A study finds that adjunctive use of GLP-1 receptor agonists before and after undergoing bariatric surgery produces greater ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Across these trials, 1.35% (279 of 20,598) of participants who received a GLP-1 RA had ≥1 episode of AFib reported as a serious adverse event, compared with 1.37% (282 of 20,608) of those who ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs ...

GLP-1 RAs can reduce liver fat, fibrosis progression, and resolve MASH, offering potential benefits for liver health. MASH significantly increases healthcare costs due to comorbidities like ...